Company intelligence / Profile preview

Micillic

Not specified, likely United Kingdom or international presence based on trademark registration.micillic.com ↗

Ownership: Private
Development stage: Commercial

Overview

Micillic has completed Phase 3 clinical trials for its proprietary probiotics and PTS-CoQ10 technologies targeting neurodegenerative diseases. The company’s research demonstrates potential benefits in managing conditions such as Alzheimer’s and Parkinson’s disease by leveraging the gut-brain axis with advanced probiotics and a highly bioavailable form of Coenzyme Q10.[2]

Therapeutic areas: Neurology
Modalities: ProbioticSmall molecule (Coenzyme Q10, as CereQ10)Nanoparticle (nano-micelle technology)[1][2]
Industry: Biotech

Drug pipeline

1 asset

Probiotic K10

Unknown

Beyond the preview

Go deeper on Micillic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micillic.

Explore the full profile